Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients
Andrea Pascual-Oliver, Diego Casas Deza, Camila Cuarán, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 6, pp. 922-929
Closed Access | Times Cited: 11

Showing 11 citing articles:

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Leticia Rodríguez-Alcolado, Elena Grueso-Navarro, Ángel Arias, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 7, pp. 1034-1052
Closed Access | Times Cited: 6
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease
Pierluigi Puca, I. Capobianco, Gaetano Coppola, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2789-2789
Open Access | Times Cited: 6
Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
Anna Pau, Ilaria Galliano, Elisa Barnini, et al.
Medicina (2025) Vol. 61, Iss. 1, pp. 102-102
Open Access
Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn’s disease
Fang Wang, He Zhou, Yujie Zhang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Personalised therapy in inflammatory bowel disease
Paula Calderón, Paulina Núñez, Pilar Nos, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 763-770
Closed Access | Times Cited: 2
Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease
Pilar Navajas Hernández, Samer Mouhtar El Hálabi, Ana Caridad González Parra, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Terapia personalizada en la enfermedad inflamatoria intestinal
Paula Calderón, Paulina Núñez, Pilar Nos, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 7, pp. 763-770
Closed Access | Times Cited: 3
Progress in the Study of Inflammatory Bowel Disease Patients with Primary Non-Responsiveness
Yixue Liu, Xiaoping Tan
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 01, pp. 72-85
Open Access
Does HLA‐DQA1*05 carriage have a greater impact on the outcome of infliximab therapy for isolated small‐bowel Crohn's disease?
Juan Wu, Nannan Zhu, Jing Hu, et al.
International Journal of Immunogenetics (2024) Vol. 51, Iss. 6, pp. 380-387
Closed Access
Real-World Experience Of The Association of HLADQA1*05 Allele with Loss of Response to Anti-TNF Inhibitors
Aastha Chokshi, Christina Raker, Sean Fine
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 4
Open Access
HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease
Jayne Doherty, Anthony W. Ryan, Emma M. Quinn, et al.
Inflammatory Bowel Diseases (2024)
Closed Access
Page 1

Scroll to top